Oriola Oyj

OKDBV

FI0009014351

Pharmaceuticals

Market Closed - Nasdaq Helsinki Other stock markets 11:29:38 2024-04-19 am EDT			5-day change	1st Jan Change
1.04 ^EUR	+0.19%		-2.44%	-4.41%

Mar. 19	Oriola Corporation Approves Dividend for the Financial Year Ending 31 December 2023, Payable on 11 April 2024	CI
Feb. 16	Oriola Oyj Proposes Dividend for the Financial Year Which Ended 31 December 2023, Be Paid on 11 April 2024	CI

Oriola Corporation - Managers' Transactions

November 12, 2021 at 07:02 am EST

Oriola Corporation - Managers' Transactions

Oriola Corporation Managers' transactions November 12, 2021 at 2:00 p.m.

Oriola Corporation - Managers' transactions - Pamp
____________________________________________

Person subject to the notification requirement
Name: Pamp, Fredrik
Position: Other senior manager
Issuer: Oriola Corporation
LEI: 549300UWB1AIR85BM957

Notification type: INITIAL NOTIFICATION
Reference number: 549300UWB1AIR85BM957_20211111134311_220
____________________________________________

Transaction date: 2021-11-10
Venue: XHEL
Instrument type: SHARE
ISIN: FI0009014351
Nature of the transaction: ACQUISITION

Transaction details
(1): Volume: 1274 Unit price: 1.9758 EUR

Aggregated transactions
(1): Volume: 1274 Volume weighted average price: 1.9758 EUR

Oriola Corporation
Sari Pohjonen
CFO

For further information, please contact:

Petter Sandström
General Counsel
tel. +358 10 429 5761
e-mail: petter.sandstrom@oriola.com

Katja Graff
Manager, Treasury and IR
tel. +358 10 429 013
e-mail: katja.graff@oriola.com

http://publish.ne.cision.com//Release/ViewReleaseHtml/2D65243ED162E3F7E0C856B0705FC7D6

© Acquiremedia - 2021

Latest news about Oriola Oyj

Oriola Corporation Approves Dividend for the Financial Year Ending 31 December 2023, Payable on 11 April 2024	Mar. 19	CI
Oriola Oyj Proposes Dividend for the Financial Year Which Ended 31 December 2023, Be Paid on 11 April 2024	Feb. 16	CI
Transcript : Oriola Oyj, 2023 Earnings Call, Feb 16, 2024	Feb. 16
Oriola Oyj Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 16	CI
Swedish Watchdog Starts Phase Two Inquiry into Oriola’s Dose Dispensing Unit Sale	Jan. 31	MT
Eva Nilsson Bågenholm Not to Stand for Re-Election as Board of Directors of Oriola Corporation	Jan. 24	CI
Oriola Plans EUR35 Million Investment in Resource Planning, Warehouse Systems Upgrade	Jan. 10	MT
Oriola Oyj Reports Impairment Charges for the Third Quarter of 2023	23-10-31	CI
Transcript : Oriola Oyj, Nine Months 2023 Earnings Call, Oct 31, 2023	23-10-31
Oriola Oyj Announces Dividend Policy	23-10-31	CI
Oriola Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31	CI
ApotekstjÄNst Sverige Ab signed an agreement to acquire Svensk Dos AB from Oriola Oyj.	23-10-12	CI
Oriola Oyj(HLSE:OKDBV) dropped from S&P Global BMI Index	23-09-18	CI
Orion and Oriola to Continue Partnership in Finland	23-09-04	CI
Transcript : Oriola Oyj, H1 2023 Earnings Call, Jul 21, 2023	23-07-21
Oriola Oyj Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-21	CI
Oriola Oyj Announces Appointment of Niklas Lindholm, Ph. D. as Chief People Officer	23-05-23	CI
Transcript : Oriola Oyj, Q1 2023 Earnings Call, Apr 27, 2023	23-04-27
Oriola Oyj Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Oriola Oyj Approves Payment of Dividend for the Financial Year Ending 31 December 2022, Payable on 14 April 2023	23-03-21	CI
Transcript : Oriola Oyj - Shareholder/Analyst Call	23-03-21
Oriola Oyj Announces Resignation of Elina Niemelä as Chief People Officer	23-03-03	CI
Panu Routila, Juko-Juho Hakala and Lena Ridström Not to Stand for Re-Election as Board of Directors of Oriola Corporation	23-02-16	CI
Transcript : Oriola Oyj, 2022 Earnings Call, Feb 16, 2023	23-02-16
Oriola Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI

Chart Oriola Oyj

Duration

Period

More charts

Company Profile
Oriola Oyj, formerly known as Oriola-KD Corporation Oyj, is a Finland-based company active in the pharmaceutical sector. The Company is engaged in the retail and wholesale of pharmaceuticals, acting as a channel between pharmaceutical manufacturers and consumers, primarily in Finland and Sweden. The Company's reporting segments are Consumer, Services, and Healthcare. Through its own pharmacies, the Company provides consumers with not only medicines and pharmaceutical advice but also a selection of healthcare consumer products and customer service. The Company is active through a number of subsidiaries located throughout Europe, including PharmaService OY, Oriola AB, Oriola Oyj, Farenta Oy, Kronans Droghandel Apotek AB and Svensk dos AB.
Sector
Pharmaceuticals
Calendar
2024-04-25 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution
More financial data

Ratings for Oriola Oyj
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
1.04 EUR
Average target price
1.175 EUR
Spread / Average Target
+12.98%
Consensus

EPS Revisions
Estimates Revisions

Quarterly earnings - Rate of surprise
Company calendar

Sector Pharmaceuticals Wholesale
1st Jan change Capi.
ORIOLA OYJ
-4.41% 208M
MCKESSON CORPORATION
+13.36% 68.18B
CARDINAL HEALTH, INC.
+7.33% 25.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD
+6.34% 7.99B
SINOPHARM GROUP CO. LTD.
-2.79% 7.88B
HUADONG MEDICINE CO., LTD
-24.02% 7.62B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD
+21.83% 4.45B
EBOS GROUP LIMITED
-2.28% 3.89B
GALENICA AG
-3.51% 3.82B
CHINA NATIONAL MEDICINES CORPORATION LTD.
+25.02% 3.69B
Pharmaceuticals Wholesale

	1st Jan change	Capi.
ORIOLA OYJ	-4.41%	208M
MCKESSON CORPORATION	+13.36%	68.18B
CARDINAL HEALTH, INC.	+7.33%	25.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+6.34%	7.99B
SINOPHARM GROUP CO. LTD.	-2.79%	7.88B
HUADONG MEDICINE CO., LTD	-24.02%	7.62B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+21.83%	4.45B
EBOS GROUP LIMITED	-2.28%	3.89B
GALENICA AG	-3.51%	3.82B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+25.02%	3.69B

Oriola Oyj

Equities

OKDBV

FI0009014351

Pharmaceuticals

Oriola Corporation - Managers' Transactions

EPS Revisions